(Q36179710)

12 August 2017

Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update (English)

1 reference

12 August 2017

1 reference

Spack EG

1

1 reference

PubMed ID

15989576

12 August 2017

language of work or name

English

0 references

publication date

1 November 1997

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

6

1 reference

12 August 2017

1715-1727

1 reference

12 August 2017

11

1 reference

Oral tolerance for the treatment of autoimmune diseases

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Oral tolerance: immune mechanisms and treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

T cell vaccination: clinical application in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

T cell receptor peptides in treatment of autoimmune disease: rationale and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Experimental immunotherapies for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Multiple sclerosis: the proinflammatory cytokines lymphotoxin-alpha and tumour necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Some misconceptions about understanding autoimmunity through experiments with knockouts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Late complications of immune deviation therapy in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Creation of a model for multiple sclerosis in Callithrix jacchus marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

The effect of intrathecal MBP synthetic peptides containing epitope P85 VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

Treatment of Uveitis by Oral Administration of Retinal Antigens: Results of a Phase I/II Randomized Masked Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.11.1715

10.1517/13543784.6.11.1715

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15989576